Purpose: To compare the feasibility and safety of proximal cerebral protection to a distal filter during carotid artery stenting (CAS) via a transbrachial (TB) or transradial (TR) approach. Methods: Among 856 patients who underwent CAS between January 2007 and July 2015, 214 (25%) patients (mean age 72±8 years; 154 men) had the procedure via a TR (n=154) or TB (n=60) approach with either Mo.MA proximal protection (n=61) or distal filter protection (n=153). The Mo.MA group (mean age 73±7 years; 54 men) had significantly more men and more severe stenosis than the filter group (mean age 71±8 years; 100 men). Stent type and CAS technique were left to operator discretion. Heparin and a dedicated closure device or bivalirudin and manual compression were used in TR and TB accesses, respectively. Technical and procedure success, crossover to femoral artery, 30-day major adverse cardiovascular/cerebrovascular events (MACCE; death, all strokes, and myocardial infarction), vascular complications, and radiation exposure were compared between groups. Results: Crossover to a femoral approach was required in 1/61 (1.6%) Mo.MA patient vs 11/153 (7.1%) filter patients mainly due to technical difficulty in engaging the target vessel. Five Mo.MA patients developed acute intolerance to proximal occlusion; 4 were successfully shifted to filter protection. A TR patient was shifted to filter because the Mo.MA system was too short. CAS was technically successful in the remaining 55 (90%) Mo.MA patients and 142 (93%) filter patients. The MACCE rate was 0% in the Mo.MA patients and 2.8% in the filter group (p=0.18). Radiation exposure was similar between groups. Major vascular complications occurred in 1/61 (1.6%) and in 3/153 (1.96%) patients in the Mo.MA and filter groups (p=0.18), respectively, and were confined to the TB approach in the early part of the learning curve. Chronic radial artery occlusion was detected by Doppler ultrasound in 2/30 (6.6%) Mo.MA patients and in 4/124 (3.2%) filter patients by clinical assessment (p=0.25) at 8.1±7.5-month follow-up. Conclusion: CAS with proximal protection via a TR or TB approach is a feasible, safe, and effective technique with a low rate of vascular complications.
Introduction
Carotid artery stenting (CAS) is a recognized treatment for carotid artery disease that has reliable results in registries and controlled randomized trials, including studies enrolling "high-surgical-risk" patients. 1 Usually, the procedure is performed transfemorally due to operator experience with this vascular approach and the femoral artery's large size, which allows the use of a wide selection of devices. However, anatomy variants of the aortic arch and supra-aortic vessels can make selective catheterization of the carotid arteries problematic or even impossible by the femoral route. 2, 3 Indeed, advancing catheters in diseased vessels with complex takeoffs may be difficult and time-consuming and may require several attempts with different catheters, increasing the risk of cerebral embolization. [4] [5] [6] Thus, an alternative vascular approach has been advocated in patients with challenging anatomies.
Transradial (TR) cardiac catheterization and percutaneous coronary intervention increased worldwide due to reduced bleeding complications, decreased mortality in myocardial infarction (MI), lower cost, and patient satisfaction and preference. 7 This approach has also been proposed for treatment of peripheral arteries, including extracranial carotid vessels. [8] [9] [10] However, compared with TR coronary interventions, CAS via the radial artery is more demanding owing to the need for dedicated systems and techniques and is associated with a steep learning curve. Moreover, the small size of the radial artery may preclude the use of large-diameter devices (>6-F), including proximal embolic protection systems. Although the brachial artery may be a valid alternative in selected cases, its use is not recommended because of a higher rate of vascular complications. 11, 12 For these reasons, previous studies frequently excluded patients with complex aortic arch anatomy and high-risk carotid plaques who could derive more benefit from TR CAS and proximal protection. Indeed, this combined strategy has been used in anecdotal cases and small patient series only. 13, 14 Recently, good results without major vascular complications were reported with TR or transbrachial (TB) CAS in 60 patients with left internal carotid artery (ICA) stenosis and bovine aortic arch, including an 8-F proximal protection device in 14 (23%). 15 These favorable results prompted us to expand this treatment strategy in other anatomic and clinical scenarios, such as the herein reported results of proximal cerebral protection vs a distal filter during CAS via a TR or TB approach.
Methods

Study Design
The TR approach for CAS was initiated in our department in January 2007. In the first 100 cases (learning curve), selected patients had very particular vascular anatomies, such as bovine aortic arch with left ICA stenosis, type II or III aortic arch with right ICA stenosis, and ICA stenoses with disease of the aortic arch or iliofemoral arteries. Thereafter, all patients with >75% asymptomatic carotid stenosis or >50% symptomatic carotid artery stenosis by Doppler ultrasound and computed tomography angiography (CTA) 16 scheduled for CAS were included. The CAS technique (ie, type of stents and cerebral protection, lesion predilation vs direct stenting, anticoagulation regimen, and closure technique) was left to operator discretion but followed our departmental protocol ( Figure 1 ) for TR/TB CAS. The study protocol was approved by the local ethical committee, and all patients gave informed consent for the procedure.
Endovascular Treatment
A 4-step algorithm ( Figure 1 ) was used to guide TR/TB CAS. First, proximal or distal cerebral protection was selected. The decision was mainly driven by carotid stenosis severity, plaque composition, distal ICA anatomy, and intracranial collateral circulation as assessed by both Doppler ultrasound and CTA. Proximal protection was selected primarily for symptomatic patients and those with lipid-rich plaque. Proximal protection was applied with the Mo.MA Ultra device (Medtronic, Santa Rosa, CA, USA) and distal protection with either the FilterWire EZ (Boston Scientific, Marlborough, MA, USA) or SpiderRx (Medtronic/Covidien, Minneapolis, MN, USA).
The second step was the choice of the vascular approach (radial vs brachial artery). Radial/brachial artery suitability was assessed through arterial pulse assessment based on our wide experience in transradial coronary interventions (~2000 procedures per year, >70% by the TR approach). If both arteries were deemed suitable, the radial approach was usually preferred in case of filter protection, whereas either the radial or brachial approach was considered if proximal protection was selected. In women, particularly if they had previous radial artery catheterization or a poor radial pulse, the brachial artery approach was the first choice.
The third step was the choice of CAS equipment (guide/ sheath and type of stent). The decision was made according to common carotid artery (CCA) diameter (≤8 or >8 mm) by CTA. For example, in cases of filter use and a ≤8-mm CCA diameter, a 6-F guide with 5-F-compatible stent [ie, Carotid Wallstent (Boston Scientific) and/or PrecisePro Rx (Cordis Corporation, Bridgewater, NJ, USA, USA)] were selected, whereas if the CCA diameter was >8 mm, a 6-F introducer sheath [Destination (Terumo, Tokyo, Japan) or Shuttle Flexor (Cook, Bloomington, IN, USA)] was preferred, which would allow the delivery of any stent size. On the other hand, if proximal protection was selected, the same 5-F-compatible stents used with filters were chosen if the CCA diameter was ≤8 mm, whereas if the diameter were >8 mm, the 5-F-compatible Cristallo Ideale hybrid stent (Medtronic) was chosen since it fits an artery as large as 10 mm. The choice of stent design (open-vs closed-cell) was left to the operator's discretion, selected mainly according to plaque composition and patient symptoms.
The final step was the CAS anticoagulation protocol and artery closure technique. A dedicated hemostasis protocol was used in all patients, as previously reported. 17 An intravenous standard dose (70 U/kg) of heparin targeting a >250-second activated coagulation time plus closure with TR-band (Terumo) were used in the TR patients. In TB approaches, intravenous bivalirudin (0.75 mg/kg bolus plus 1.4-1.75 mg/kg/h infusion according to creatinine clearance up to the end of the procedure) and manual compression were chosen. Bivalirudin was preferred in the TB approach due to the quick (~1 hour after stopping drug infusion) and predictable reversal of the anticoagulation effect allowing safe sheath removal and hemostasis by manual compression. 18 
CAS Technique
After local anesthesia, the right radial or right brachial artery was punctured with a 20-G needle, and a 6-F (or 8-F in case of Mo.MA), 11-cm-long Terumo sheath (Terumo) was inserted. Then 2.5 mL of a 100-mL solution made with 50,000 units of heparin + 20 mg verapamil + 4 mg nitroglycerine was administered through the sheath. The CAS technique was the same regardless of the vascular approach. The preferred projections used were the posteroanterior view and the 45° left and right oblique for the left and right ICA, respectively. The target CCA was cannulated using 5-F diagnostic catheters over a 0.035-inch, 260-cmlong Terumo wire. The right Judkins, internal mammary, or Simmons 1 catheters (according to the right subclavian artery/right CCA bifurcation anatomy) were used for either the right or left CCA within a bovine configuration, whereas the Simmons 1 or 2 catheter was used in those with left CCA takeoff from the aorta.
Carotid and intracranial angiography was performed at baseline and at the end of the procedure. Using the roadmap technique, the Terumo wire was placed deep into the external carotid artery (ECA), and the diagnostic catheter was advanced over it for exchange of the Terumo wire for a stiff 0.035-inch Magic Torque wire (Boston Scientific) or Supracore wire (Abbott Vascular, Santa Clara, CA, USA). After removing the diagnostic catheter, a 6-F guide (right Judkins or multipurpose) or a 6-F, 90-cm-long introducer sheath was selected according to the distal left CCA diameter. If advancement of the guide/sheath over the stiff wire was difficult, the telescoping technique was used with a 4-F, 125-cm-long multipurpose catheter loaded into the guide/ sheath. The Mo.MA or filter was positioned. Lesion predilation was performed using coronary balloons (3.5 to 4.0×30 mm). After administration of atropine (0.5-1 mg), all stents were postdilated using short, noncompliant balloons. The protection device was then removed, final angiography was performed, and the introducer sheath or guiding catheter was withdrawn. As mentioned above, hemostasis was obtained with manual compression for the TB approach and with a dedicated system for TR procedures.
Neurological evaluation was performed by an experienced neurologist (L.C.) in all cases before the procedure, after CAS, and at 30 days. In-hospital and 30-day clinical forearm inspection and pulse palpation of the radial or brachial artery were performed in all patients. Radial artery patency was assessed at follow-up with Doppler ultrasound in patients who underwent TR CAS with the Mo.MA device. Radial artery occlusion was defined as the absence of Doppler flow. Clinical follow-up beyond 30 days, including brachial or radial artery assessment, was carried out at 6 and 12 months and yearly thereafter.
Patient Sample
Among 856 patients who underwent CAS between January 2007 and July 2015, 214 (25%) patients (mean age 72±8 years; 154 men) had the procedure via either a TR (n=154) or TB (n=60) approach. The distribution of risk factors was typical in the study population (Table 1) : More than half of the patients (135, 63%) were at "high surgical risk," 77 (36%) were ≥75 years of age, and most (203, 95%) had no symptoms. Proximal protection was used in 61 (28%) patients (mean age 73±7 years; 54 men) and distal protection in 153 patients (mean age 71±8 years; 100 men). Besides having significantly more men, the proximal protection group had more severe stenosis (88%) than the filter group (83%).
Study Endpoints
The following parameters were assessed: (1) composite endpoint of 30-day major adverse cardiovascular/cerebrovascular events (MACCE), defined as death, all strokes, and MI;
(2) crossover rate, which referred to a shift from a TR or TB access to the transfemoral approach; (3) technical success [successful stent positioning and <30% residual carotid stenosis by NASCET (North American Symptomatic Carotid Endarterectomy Trial Collaborators) criteria]; (4) clinical success (technical success without MACCE); and (5) vascular complications, which included any bleeding associated with a hemoglobin loss of at least 2 g/L, blood transfusion, vascular repair (major), prolonged hospitalization (major), or bleeding at the access site resulting in hematoma that did not require specific therapy (minor).
Statistical Analysis
Numerical variables are summarized as mean ± standard deviation or median and interquartile range as appropriate. Categorical variables are summarized as numbers and percentages. Clinical and ultrasound/CTA characteristics were compared using the Student t test or Wilcoxon rank-sum test; categorical data were compared using a chi-square or Fisher exact test, as appropriate. The analysis of covariance was used to compare the time course over years for dose area product in the groups. A 2-sided p<0.05 was considered significant. All analyses were performed using the SAS Statistical Package (version 9.4; SAS Institute Inc, Cary, NC, USA).
Results
CAS With Mo.MA Protection
Of the 61 patients undergoing CAS with proximal protection, 30 had a right TR access and 31 had a TB approach ( Table 2) . The target vessel was the right ICA in 26 (43%) patients and the left ICA in 35 (57%) patients. The most common anatomy was left ICA stenosis with bovine configuration in 32 (52%) of 61 patients. Overall, the Mo.MA system could not be positioned in 1 of 61 cases (1.6% crossover to femoral access) due to hostile anatomy of the right subclavian artery and right CCA bifurcation in 1 patient. Five (8.1%) patients were intolerant to proximal occlusion (Table 3 ) and required system declamping; 4 were converted to distal protection. In 1 patient, neurologic symptoms developed during final blood aspiration and resolved spontaneously with CCA balloon deflation. In all cases, symptoms were quickly relieved after blood flow restoration. One patient was shifted to filter because the Mo.MA was too short to engage the ECA from the TR access in a case of left ICA stenosis and bovine arch. In the remaining 55 (90%) patients, CAS was successfully performed under Mo.MA protection with no MACCE. In 16 patients, the first attempt to position the Mo.MA system into the target vessel failed due to an extremely unfavorable anatomy (Figure 2 ). In these cases, the standard implantation technique was modified by removing the device mandrel and adding a second wire in the main channel (the so-called No-mandrel 2-wire or "No.Ma2" technique, Figure 3 ). This technique led to successful Mo.MA positioning in all 16 cases (Figure 4 ). In 4 patients who showed either ECA occlusion (n=1) or severe ECA stenosis that could not be crossed by the wire, the Mo.MA Ultra mono balloon was used either alone (n=1) or combined with a distal filter (n=3). One major vascular complication occurred (brachial artery pseudoaneurysm) and was successfully repaired surgically.
At an average follow-up of 8.1±7.5 months, radial artery occlusion was detected by Doppler ultrasound in 2 (6.6%) of 30 patients. Fluoroscopy time (p=0.018) and contrast medium volume (p<0.001) were significantly lower in the Mo.MA group as compared with the filter group (Table 3 ). While no difference was detected in the average radiation exposure as compared to CAS with filter, there was a significant decrease in this value over time regardless of the target carotid artery ( Figure 5 ).
CAS With Filter Protection
Of the 153 patients undergoing CAS with a distal filter, 124 had a TR access and 29 a TB approach. The target vessel was the right or left ICA in 56% and 44% of patients, respectively ( Table 2 ). In 11 (7.1%) patients, failure to engage the target vessel (left or right ICA in 5 and 6 cases, respectively) forced conversion to the femoral approach. Technical and procedural success rates were 100% and 98%, respectively. The in-hospital/30-day composite MACCE rate was 2.8% (4/142, per protocol analysis). Overall, 1 major and 2 minor strokes and a retinal embolism occurred; no death or MI was observed. Two patients had transient ischemic attack that resolved in the catheterization laboratory (4.2% overall complication rate, including transient ischemic attack).
Vascular complications occurred in 3 (1.96%) of 153 patients (Table 3) , all in the TB group. Two patients had brachial artery subacute thrombosis and 1 patient developed a brachial artery pseudoaneurysm (Table 4 ); all were successfully treated by surgical intervention. In 4 (3.2%) of 124 patients, radial artery occlusion was detected by clinical assessment. Similar to the Mo.MA group, there was a significant trend toward reduced radiation exposure over the years ( Figure 5 ).
Discussion
There is increasing evidence suggesting that the flow arrest/ reversal technique may offer better brain protection against microembolization compared to distal protection with filter devices. [19] [20] [21] [22] Despite anecdotal cases and small series reporting favorable results of TR CAS with proximal protection, 13, 14 this technique has not gained widespread acceptance yet, likely because the size (8-F) and stiffness of the proximal protection device make radial access and navigation in the complex anatomy of the supra-aortic vessels difficult. The best indicator of feasibility of TR CAS is the rate of crossover to a transfemoral approach, mainly due to difficulties in target vessel engagement. A 5% to 9% crossover rate has been reported in 2 previous studies including >500 patients submitted to TR CAS with filter protection. 9, 10 These data are in agreement with the 7.1% rate observed in the filter group of the present study, while the 1.6% rate of the Mo.MA group compares favorably with distal protection.
Interestingly, engagement difficulties were mostly due to takeoff characteristics of the target CCA. In fact, while left ICA stenoses in patients with bovine arch were easily addressed due to the favorable right subclavian-innominate-left CCA pathway, 15 we failed to position the Mo.MA device at the first attempt in the right and left ICA, but not when the bovine CCA was present, in 43% and 100% of patients, respectively. The initial technical failure was due to a combination of factors, including sharp takeoff angle (<45°) of the target vessel, lack of anatomic support, and Mo.MA system stiffness. These factors ultimately led to prolapse of the entire system into the innominate artery or the aortic arch. To overcome these problems, we reduced the Mo.MA system stiffness by removing the mandrel and improved its deliverability by increasing support with an additional stiff or standard wire. The new strategy, called the "No.Ma2" (No-Mandrel 2-wire) technique, requires the positioning of a second wire into the ECA through a 6-F guide. The Mo.MA system is then loaded over the 2 wires (one into the ECA and the second into the main channel) and advanced into the target vessel with a "push-and-pull" movement, making sure to keep the wires parallel during the entire maneuver. With this technique, we succeeded in correctly positioning the Mo.MA system in all cases. Thus, we recommend starting with this technique in patients sharing a similar aortic arch anatomy to reduce procedure time and the risk of microembolization due to prolonged catheter manipulation.
Severe disease of the carotid artery bifurcation and ECA occlusion are contraindications to proximal protection use. However, the 8-F mono occlusion balloon version of the Mo.MA system may be used in these cases. The main difference from the standard Mo.MA Ultra system is the absence of the catheter extension for the ECA. While this device may look easier to handle than the standard device, this is not always the case, especially through the TR approach. In fact, the ECA occlusion does not allow positioning a stiff wire deep into this vessel to support device advancement. Moreover, the short protrusion of the mandrel outside the working channel ( Figure 6A ) further reduces device trackability and pushability. 9 Hostile anatomy in all 10 (13/130) 10 6 Hostile anatomy Crossover to filter 9 1 Death, 1 major and 3 minor strokes 0.9 (1/117) 10 1 6.0 (23/347) 9 5-6-F IS in 85% 6.8 (8/117) 10 7-F GC in 90% These limitations may be overcome with 2 techniques. The first is the "wire reshaping" technique that keeps the wire below the bifurcation, limiting the risk of inadvertently crossing the lesion, maintaining good support for advancing the whole system. 23 The second is the use of the Mo.MA mono balloon without the Y-connector, allowing the mandrel to stick out 8.5 cm of the catheter tip ( Figure  6B) . Alternatively, the mandrel can be exchanged for a 4-F, 125-cm-long multipurpose catheter that provides a longer transition zone (up to 20 cm; Figure 6C ). If these strategies fail, the No.Ma2 technique can be used. The second wire is advanced below the bifurcation using the same technique, and both wires are loaded into the main channel of the device after the mandrel has been removed. We successfully used this technique in 2 patients with challenging anatomy (Figure 7) . Thus, the Mo.MA mono occlusion balloon may widen the applicability of TR CAS with proximal protection in complex patient and anatomy subsets.
Radiation exposure is an important issue in percutaneous interventions. 24 A 29% increase in radiation exposure has been reported for TR CAS as compared with transfemoral CAS. 10 Proximal protection may further increase fluoroscopy time owing to difficulties in accessing the target vessel. However, in our study there was no difference in radiation dose between groups. Moreover, there was a trend toward gradual dose reduction over years regardless of the type of brain protection, a clear indication of the learning curve impact.
Stabile et al 19 reported a complication rate as low as 1.36% in 1300 consecutive patients undergoing CAS with proximal protection via the femoral artery. Favorable results included high-risk subsets of patients such as the elderly and symptomatic. As regards post-CAS cerebral lesions assessed by nuclear magnetic resonance, a trend in favor of proximal vs distal protection was found in a recent metaanalysis. 22 In the present study, the MACCE rate was 0% in Mo.MA patients and 2.8% in filter cases. This difference may be due to the small number of patients treated with Mo.MA. Alternatively, since proximal protection was introduced in the late period of the TR CAS learning curve, it may be the result of better operator experience. Indeed, all MACCE of the filter group clustered in the early phase of the learning curve. Nevertheless, it should be noted that proximal protection was used in a higher proportion of high-surgical-risk patients with more severe carotid stenosis. Thus, further studies in a greater number of patients are warranted to confirm these initial results and to understand whether proximal protection through the TR approach is associated with a better outcome.
Coronary intervention performed via a TR approach has been shown to significantly reduce bleeding and vascular complications compared to femoral or TB catheterization. 12 The less favorable results with the TB approach are likely due to difficulties in compressing the vessel in heparinized patients and may explain the reluctance to use large devices through this artery. In our series, major vascular complications occurred in 1.9% of all patients, 1 in the Mo.MA group and 3 in the filter group. Of note, all events occurred in the TB subgroup and were confined to the early period of the learning curve (4 of 24 patients between 2007 and 2009). Since the last vascular complication, we replaced heparin with bivalirudin to take advantage of the quick (~1 hour after infusion) and predictable disappearance of the anticoagulation effect that allows effective hemostasis of the artery puncture site. 18 Indeed, no other vascular complications occurred in the following 36 patients in whom bivalirudin infusion was stopped at the time of stent implantation and the sheath was removed 30 minutes after the procedure. While bivalirudin has been associated with a significant reduction in bleeding compared to unfractionated heparin in transfemoral CAS, 25 its superiority in TR/TB CAS needs additional studies to be confirmed.
The most frequent complication of TR catheterization is radial artery occlusion, which ranges from 6% to 35% according to the modality used for diagnosis. 26 Several factors seem to be involved, including guide catheter size, with rates ranging between 1% and 7%, 6% and 11%, and 11% for 5-F, 6-F, and 8-F catheters, respectively. 27, 28 Saito et al 29 showed that only 45% of men and 24% of women scheduled for TR coronary intervention had a radial artery size matching an 8-F device diameter. In our patients, the TR approach was chosen when a good radial pulse was present, potentially indicating a suitable artery size. Our 6.6% (2/30) rate of Doppler-detected radial artery occlusion is in agreement with previous reports 9, 10, 30, 31 in which radial artery occlusion was assessed by standard clinical evaluation. A proper pre-CAS radial artery size selection (ie, ≥3.0 mm by Doppler ultrasound), the reduction of catheter exchanges, and the prevention of radial spasm with appropriate drugs 28, 32 may play a role in preventing this complication. Finally, patency-documented hemostasis may be of additional value and should be adopted in all patients. 17 
Limitations
Our study enrolled a small group of patients who were treated by operators with longstanding experience in TR and TB interventions in a single, high-volume center (~100 CAS procedures per year). Only 2 distal filters and one type of proximal protection were used in conjunction with selected stents based on operator preference and familiarity with the devices. Thus, these results may not necessarily reflect the patient population of other centers or countries and should be confirmed by further studies, including randomized controlled trials.
Conclusion
Based on our experience, TR/TB CAS is feasible and accommodates the full spectrum of CAS devices and techniques, including proximal embolic protection, allowing wider application of this technique to patients with highrisk plaque, clinical symptoms, and hostile anatomy.
Moreover, TR/TB CAS achieves similar technical and procedure success rates with few vascular complications using either distal or proximal protection. Our 4-step algorithm may help operators select appropriate TR/TB CAS patients, techniques, and equipment. Systematic use of carotid CTA and a sound experience in TR interventions are mandatory.
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